Uptrend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Oct 2 · above the Ichimoku cloud · RSI 84 (overbought) · MACD above its signal
None of the 29 investors followed here reported a position in ZIVO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ZIVO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Apr 16, 2026 | Strome Mark E.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 2.00 per share. | 100K | $200.00K |
| Feb 26, 2026 | Yaldoo Laith LDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 9.72 per share. | 1.5K | $15.00K |
| Feb 11, 2026 | Strome Mark E.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 9.77 per share. | 20K | $195.40K |
| Feb 9, 2026 | Yaldoo Laith LDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 10.27 per share. | 2.4K | $25.00K |
| Jan 25, 2026 | Cornell Alison ADirector | Purchase at price 8.54 per share. | 11.7K | $100.00K |
| Jan 25, 2026 | Payne John BernardChief Executive Officer | Purchase at price 8.54 per share. | 11.7K | $100.00K |
| Jan 13, 2026 | Maggiore Christopher DDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 8.49 per share. | 1.8K | $14.99K |
| Jan 13, 2026 | Yaldoo Laith LDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 8.49 per share. | 1.8K | $14.99K |
| Nov 27, 2025 | Yaldoo Laith LDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 9.00 per share. | 2.8K | $24.99K |
| Oct 12, 2025 | Strome Mark E.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 12.34 per share. | 20.3K | $250.00K |
| Oct 9, 2025 | Yaldoo Laith LDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 12.05 per share. | 1.7K | $19.99K |
| Oct 7, 2025 | Maggiore Christopher DDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 12.01 per share. | 23.7K | $284.42K |
| Sep 29, 2025 | Yaldoo Laith LDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 15.99 per share. | 15.3K | $245.00K |
| Jun 12, 2025 | Yaldoo Laith LDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 14.33 per share. | 3.5K | $49.98K |
| Apr 7, 2025 | Maggiore Christopher DDirector and Beneficial Owner of more than 10% of a Class of Security | Sale at price 16.25 per share. | 20 | $325 |
| Jan 21, 2025 | Yaldoo Laith LDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 17.53 per share. | 10.1K | $176.68K |
| Dec 30, 2024 | Masterson Nola EDirector | — | 8.9K | — |
| Dec 30, 2024 | Maggiore Christopher DDirector and Beneficial Owner of more than 10% of a Class of Security | — | 8.6K | — |
| Dec 30, 2024 | Cornell Alison ADirector | — | 9.8K | — |
| Dec 30, 2024 | Yaldoo Laith LDirector and Beneficial Owner of more than 10% of a Class of Security | — | 11.1K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 20.7 | -10.5 | -28.2 | -47.7 | 24.6 | -8.4 | -0.7 | 6.7 | -22.7 | 97.3 | −25.2% | ||
| 2025 | -7.9 | 0.0 | -13.6 | 9.9 | -0.4 | -20.4 | -28.2 | 59.0 | -6.0 | -12.4 | -18.7 | -23.6 | −59.5% |
| 2024 | 580.0 | -1.8 | -3.2 | 1.9 | 0.8 | -2.0 | 9.0 | 58.8 | 21.8 | 18.6 | 5.1 | 4.9 | +1691.7% |
| 2023 | 45.6 | -9.1 | -6.9 | -4.5 | -6.5 | -12.0 | -15.7 | -11.8 | -27.8 | -65.4 | -74.4 | 73.9 | −92.0% |
| 2022 | -3.1 | 27.7 | 9.3 | -17.5 | 2.5 | 19.5 | -7.7 | 3.6 | -25.3 | 11.1 | -15.8 | -4.6 | −12.9% |
| 2021 | 0.0 | 6.7 | -18.8 | 0.0 | -59.7 | 13.1 | -26.2 | -9.1 | 43.4 | -21.7 | -5.9 | -14.6 | −76.1% |
| 2020 | -11.8 | 0.0 | -20.0 | -8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 9.1 | 25.0 | -13.3 | 15.4 | −11.8% |
| 2019 | -15.4 | 0.0 | 27.3 | -21.4 | 0.0 | -9.1 | -10.0 | 0.0 | -22.2 | 14.3 | 50.0 | 41.7 | +30.8% |
| 2018 | 11.1 | 10.0 | -9.1 | -10.0 | 44.4 | 30.8 | -29.4 | 25.0 | 6.7 | -18.8 | 15.4 | -13.3 | +44.4% |
| 2017 | 10.0 | 0.0 | -27.3 | 12.5 | -22.2 | -14.3 | 0.0 | 0.0 | 50.0 | -11.1 | 50.0 | -25.0 | −10.0% |
| 2016 | -16.7 | 60.0 | 0.0 | -12.5 | 0.0 | -14.3 | -16.7 | 0.0 | 20.0 | 50.0 | 33.3 | -16.7 | +66.7% |
| 2015 | -25.0 | 66.7 | -20.0 | -12.5 | 142.9 | -23.5 | -23.1 | 20.0 | -33.3 | 0.0 | -12.5 | -14.3 | −25.0% |
| 2014 | -30.8 | 0.0 | -37.0 | 11.8 | 0.0 | -15.8 | -12.5 | -7.1 | 0.0 | -7.7 | -16.7 | -20.0 | −79.5% |
| 2013 | 42.1 | -14.8 | 34.8 | 48.4 | -10.9 | -14.6 | 31.4 | -6.5 | 4.7 | -20.0 | -19.4 | 34.5 | +105.3% |
| 2012 | -16.0 | -19.0 | 94.1 | -3.0 | -25.0 | -16.7 | -5.0 | 0.0 | -15.8 | -18.8 | -15.4 | 72.7 | −24.0% |
| 2011 | -16.7 | 6.7 | -21.9 | -24.0 | 0.0 | -26.3 | 35.7 | 68.4 | -34.4 | -19.0 | -5.9 | 56.2 | −30.6% |
| 2010 | -40.0 | 300.0 | 20.8 | 3.4 | 15.6 | -51.0 | -7.8 | -4.3 | -11.1 | -12.5 | 5.7 | -2.7 | +20.0% |
| 2009 | -20.0 | 25.0 | 0.0 | 0.0 | 10.0 | 263.6 | 10.0 | -20.5 | 34.3 | -14.9 | -22.5 | -3.2 | +200.0% |
| 2008 | 5.3 | 120.0 | -31.8 | 33.3 | 35.0 | -29.6 | -47.4 | -35.0 | -15.4 | -54.5 | 40.0 | 42.9 | −47.4% |
| 2007 | 8.7 | -10.0 | -16.7 | -40.0 | 4.4 | 25.5 | -18.6 | 10.4 | -66.0 | 5.6 | 31.6 | -24.0 | −79.3% |
No analyst coverage for this instrument.
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. It offers poultry gut health, avian influenza, bovine mastitis, canine joint health, human immune modification, human functional food ingredients, algal biomass for human food, and biomass for supporting skin health and anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Troy, Michigan.
No recent headlines.